
Tay Therapeutics in licensing deal with VYNE Therapeutics
Tay Therapeutics Ltd’s exclusive license deal with VYNE Therapeutics Inc. on the oral BET inhibitor, TAY-B2 (now known as VYN201) forsees an upfront...

Mainz Biomed Partners with Microba Life Sciences
Leveraging a platform for measuring the human gut microbiome to discover and develop novel therapeutics for major diseases, Microba and Mainz Biomed...

Carbios SAS set to licence and expand PET recycling
Carbios SAS has announced "excellent outputs" from its demonstration plant in Clermont-Ferrand and its advanced engineering study for the...

FAO presents food safety assessment on cell-based protein products
With more than 100 companies, including Israel's Aleph Farms, Holland's Mosa Meat and the UK's Higher Steaks Ltd., active in the future market of...

Phialogics AG bags pre-seed financing
Basel-based Phialogics AG, which was spun-off from Fraunhofer Institute for Immune Pathology and Immune Tolerance in 2021, has cashed in a pre-seed...

Neurodegenerative disorders are being fought with €28m
The Danish biotech Teitur Trophics ApS, aiming to treat chronic neurological disorders, has completed a €28m Series A funding. With the money, Teitur...

500 experts at the 7th AMR Conference in Basel
That antimicrobial resistance can no longer be considered a silent pandemic became abundantly clear at the AMR Conference in Basel from March 16-17....